These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 19933651

  • 1. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters.
    Riches SF, Payne GS, Morgan VA, Sandhu S, Fisher C, Germuska M, Collins DJ, Thompson A, deSouza NM.
    AJR Am J Roentgenol; 2009 Dec; 193(6):1583-91. PubMed ID: 19933651
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
    Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, deSouza NM.
    AJR Am J Roentgenol; 2007 Jan; 188(1):91-8. PubMed ID: 17179350
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
    Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA.
    J Magn Reson Imaging; 2009 Aug; 30(2):327-34. PubMed ID: 19629981
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
    Selnæs KM, Heerschap A, Jensen LR, Tessem MB, Schweder GJ, Goa PE, Viset T, Angelsen A, Gribbestad IS.
    Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.
    Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J.
    AJR Am J Roentgenol; 2007 Aug; 189(2):323-8. PubMed ID: 17646457
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging.
    Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO.
    Radiology; 2003 Oct; 229(1):248-54. PubMed ID: 12944607
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology.
    Isebaert S, De Keyzer F, Haustermans K, Lerut E, Roskams T, Roebben I, Van Poppel H, Joniau S, Oyen R.
    Eur J Radiol; 2012 Mar; 81(3):e217-22. PubMed ID: 21349667
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
    Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barceló J, Ferrer J, Albanell J.
    AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.